USPTO trademark

GENERATIVE BIOLOGICS

Opposition periodUSPTOWord and designClass 9Class 42

"GENERATIVE BIOLOGICS" is a word and design mark owned by Insilico Medicine IP Limited, filed at the USPTO on February 1, 2024. It is in its opposition period and covers classes 9 and 42.

View Insilico Medicine IP Limited portfolioGet this data via the API
Official USPTO record
GENERATIVE BIOLOGICS trademark as filed
As filed with the USPTO
Status
Opposition period
Since April 2, 2025
Filed
February 1, 2024
Registered
Not yet
Expires
Not recorded
Application no.
98387649
Registration no.
Not yet
Office
USPTO
United States Patent and Trademark Office
Mark type
Word and design
2 classes
Ownership

Who owns GENERATIVE BIOLOGICS

The owner on file, matched to the company behind it. Every owner-name spelling for that company is grouped on its page.

Owner

Insilico Medicine IP Limited

Central, Hong Kong, Hong Kong SAR China

34 trademarks in the portfolioView company

Representative

Jacqueline M. Lesser

Ice Miller LLP

Goods and services

What the mark covers

The products and services GENERATIVE BIOLOGICS is filed for, grouped by Nice class.

  • Downloadable and recorded computer software; recorded or downloadable computer software platforms using artificial intelligence for automated machine learning in the field of biologics design and development; computer operating programs, recorded; data processing apparatus

  • Technological research relating to patent mapping; scientific research and development; scientific and technical research relating to patent mapping; research in the field of artificial intelligence; research and development of new products; scientific laboratory services, namely laboratory services in biologics design and development; cancer research for medical purposes; artificial intelligence consultancy in biologics design and development, namely, chemistry services, clinical trials, biomedical research services, medical laboratory service, medical research service; design and development of computer software; design and development of computer software, namely developing customized software in the field of biologics design and development, including peptides, nanobodies, and antibodies tailored for specific targets; computer software installation, maintenance and repair and updating of computer software; installation of software using artificial intelligence for automated machine learning in the field of biologics design and development, including peptides, nanobodies, and antibodies tailored for specific targets; development of computer platforms; research in computer natural language processing; design of computer-simulated models; software as a service (SAAS) services featuring software for using artificial intelligence for automated machine learning in the field of biologics design and development, including peptides, nanobodies, and antibodies tailored for specific targets; software development in the framework of software publishing; platform as a service (PAAS) featuring computer software platforms for using artificial intelligence for automated machine learning in the field of biologics design and development, including peptides, nanobodies, and antibodies tailored for specific targets; development of computer platforms; computer system design; rental of computer software; creating and designing website based indexes of data and information for others using information technology; computer programming services; maintenance of computer software; installation of computer software; installation, maintenance, and updating of computer software

History

What has happened so far

Steps recorded by the USPTO, newest first.

  1. Extension of time to oppose process - terminated
  2. Assigned to examiner
  3. Opposition instituted no. 999999
  4. Extension of time to oppose received
  5. Official gazette publication confirmation e-mailed
  6. Published for opposition
  7. Notification of notice of publication e-mailed
  8. Approved for pub - principal register
  9. Teas/email correspondence entered
  10. Correspondence received in law office

10 earlier steps on the official record.

Disputes

Oppositions and cancellations

Proceedings recorded against this mark by the USPTO. Reported as recorded, not legal advice.

FAQ

About GENERATIVE BIOLOGICS

Who owns the trademark "GENERATIVE BIOLOGICS"?

The USPTO trademark "GENERATIVE BIOLOGICS" (application 98387649) is owned by Insilico Medicine IP Limited.

What is the status of "GENERATIVE BIOLOGICS"?

Its status at the USPTO is: opposition period.

API

Get this data via the API

Everything on this page comes from the Signa API. Pull GENERATIVE BIOLOGICS and marks like it into your own product with one request.

  • GET/v1/trademarks/{id}

    The full record: owners, classes, dates and images

  • GET/v1/trademarks/{id}/events

    Every step in the office history

  • GET/v1/proceedings?trademark_id={id}

    Oppositions and cancellations against the mark

Get API keyView docs
GET /v1/trademarks/{id}
ID=tm_019d2c8f-ac1c-73c0-9ed5-02add19139e0
curl https://api.signa.so/v1/trademarks/$ID \
  -H "Authorization: Bearer $SIGNA_API_KEY"
Response
{
  "id": "tm_019d2c8f-ac1c-73c0-9ed5-02add19139e0",
  "object": "trademark",
  "mark_text": "GENERATIVE BIOLOGICS",
  "status": {
    "primary": "pending",
    "stage": "pending_opposition"
  },
  "office_code": "US",
  "application_number": "98387649",
  "filing_date": "2024-02-01",
  "nice_classes": [
    9,
    42
  ],
  "owners": [
    {
      "name": "Insilico Medicine IP Limited",
      "entity_id": "ent_019f9eaf-333c-71d9-800f-7b0d57f1cfb5"
    }
  ]
}